QQ客服 官方微博 反馈留言

	Optimizing the treatment of bevacizumab as first-line therapy for human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: an updated meta-analysis of published randomized trials
	Li, Cunfu; Xiang, Aizhai; Chen, Xianzhi; Yin, Kai; Lu, Jinsong; Yin, Wenjin
刊名	ONCOTARGETS AND THERAPY
	2017
卷号	10
关键词	breast cancer bevacizumab first-line HER2-negative meta-analysis
ISSN号	1178-6930
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3617699
专题	复旦大学上海医学院
推荐引用方式 GB/T 7714	Li, Cunfu,Xiang, Aizhai,Chen, Xianzhi,et al. Optimizing the treatment of bevacizumab as first-line therapy for human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: an updated meta-analysis of published randomized trials[J]. ONCOTARGETS AND THERAPY,2017,10.
APA	Li, Cunfu,Xiang, Aizhai,Chen, Xianzhi,Yin, Kai,Lu, Jinsong,&Yin, Wenjin.(2017).Optimizing the treatment of bevacizumab as first-line therapy for human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: an updated meta-analysis of published randomized trials.ONCOTARGETS AND THERAPY,10.
MLA	Li, Cunfu,et al."Optimizing the treatment of bevacizumab as first-line therapy for human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: an updated meta-analysis of published randomized trials".ONCOTARGETS AND THERAPY 10(2017).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。